---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-026563"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:21:02.873016+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monopar doses first patient in Phase 1 MNPR-101-Zr trial; favorable safety and biodistribution data

## Summary
- First patient dosed in open-label Phase 1 imaging trial of MNPR-101-Zr; well-tolerated with no serious adverse reactions.
- Red bone marrow radiation dose ~14 mGy, roughly 150 times below the accepted limit of 2-3 Gy.
- No unanticipated or excessive uptake in critical organs; biodistribution aligns with preclinical data.
- Initial patient has metastatic cancer not known for high uPAR expression; study to include high-uPAR cancers.
- COO Andrew Cittadine: data increases confidence to advance Phase 1 and prepare therapeutic study.

## SEC filing metadata
- accession: 0001437749-24-026563
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924026563/0001437749-24-026563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924026563/mnpr20240812_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-026563
- JSON: https://secwatch.observer/filing/0001437749-24-026563.json
- Plain text: https://secwatch.observer/filing/0001437749-24-026563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.